[{"data":1,"prerenderedAt":180},["ShallowReactive",2],{"drug-emtricitabine-tenofovir":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":46,"contraindications":70,"warnings":80,"renal":87,"monitoring":88,"interactions":89,"review":90,"examples":93,"atc":99,"iran":101,"links":121,"populations":139,"usApproval":175},"emtricitabine-tenofovir",1,{"fa":7,"en":8},"امتریسیتابین + تنوفوویر (PrEP)","Emtricitabine + tenofovir DF (PrEP)","anti-infectives",{"fa":11,"en":12},"ضدرتروویروس","Antiretroviral",[14],{"name":15,"market":16},"Truvada","US",[18,19,20,21],"truvada","تروادا","PrEP","پرپ",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":31,"refs":32,"components":36},"tab-200-300","tablet","oral","Emtricitabine 200 mg + tenofovir DF 300 mg tablet",{"amount":29,"unit":30,"perUnit":25},200,"mg",[16],[33],{"source":34,"section":35},"fda-truvada","3",{"emtricitabine":37,"tenofovir":41},{"name":38,"amount":29,"unit":30},{"fa":39,"en":40},"امتریسیتابین","Emtricitabine",{"name":42,"amount":45,"unit":30},{"fa":43,"en":44},"تنوفوویر دیزوپروکسیل","Tenofovir DF",300,[47],{"id":48,"disease":49,"label":50,"population":53,"type":55,"unit":30,"dose":56,"refs":57,"doseComponent":60,"notes":61},"prep","hiv-prep",{"fa":51,"en":52},"پیشگیری پیش از مواجهه HIV — یک قرص روزانه (۳۵ kg به بالا)","HIV PrEP — one tablet daily (≥35 kg)",{"minWeightKg":54},35,"fixed",{"perDose":29,"dosesPerDay":5},[58],{"source":34,"section":59},"2.5","emtricitabine",[62],{"text":63,"refs":66},{"fa":64,"en":65},"دوز به‌صورت جزء امتریسیتابین (یک قرص ۲۰۰\u002F۳۰۰). منفی بودن HIV درست پیش از شروع و دست‌کم هر ۳ ماه تأیید شود.","Shown as the emtricitabine component (one 200\u002F300 tablet). Confirm HIV-negative immediately before starting and at least every 3 months.",[67,68],{"source":34,"section":59},{"source":34,"section":69},"Boxed Warning",[71],{"id":72,"severity":73,"text":74,"refs":77},"hiv","block",{"fa":75,"en":76},"برای PrEP در وضعیت HIV نامعلوم یا مثبت ممنوع.","Contraindicated for PrEP with unknown or positive HIV-1 status.",[78],{"source":34,"section":79},"4",[81],{"text":82,"refs":85},{"fa":83,"en":84},"هشدار جعبه‌ای: تشدید هپاتیت B پس از قطع؛ مقاومت دارویی HIV اگر عفونت حاد تشخیص داده نشود.","Boxed warning: hepatitis B flare after stopping; HIV drug resistance if acute infection is missed.",[86],{"source":34,"section":69},[],[],[],{"status":91,"reviewer":92,"date":92},"unverified",null,[94],{"regimen":48,"formulation":24,"input":95,"expect":98},{"ageYears":96,"weightKg":97},30,70,{"perDose":29,"tabletsPerDoseRounded":5},[100],"J05AR03",{"status":102,"forms":103,"refs":116},"registered",[104,108,112],{"code":105,"en":106,"fa":107},"21940","EMTRICITABINE 200 MG + TENOFOVIR 300MG TAB","قرص امتری‌سیتابین ۲۰۰ میلی‌گرم + تنوفوویر ۳۰۰ میلی‌گرم",{"code":109,"en":110,"fa":111},"11460","TENOFOVIR\u002FEMTRICITABINE 245\u002F200MG TAB","قرص تنوفوویر \u002F امتری‌سیتابین ۲۴۵ \u002F ۲۰۰ میلی‌گرم",{"code":113,"en":114,"fa":115},"51977","EMTRICITABINE \u002F TENOFOVIR ALAFENAMIDE (AS FUMARATE) TABLET ORAL 200 mg\u002F25 mg","قرص امتری‌سیتابین \u002F تنوفوویر آلافنامید (معادل فومارات) ۲۰۰ میلی‌گرم \u002F ۲۵ میلی‌گرم",[117],{"source":118,"section":119,"url":120},"darooyab-generic","G-4726\u002FEmtricitabine-Tenofovir","https:\u002F\u002Fwww.darooyab.ir\u002FG-4726\u002FEmtricitabine-Tenofovir",[122,126,130,133,136],{"kind":123,"url":124,"label":125},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021752","NDA021752",{"kind":127,"url":128,"label":129},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=54e82b13-a037-49ed-b4b3-030b37c0ecdd","FDA Truvada",{"kind":131,"url":132,"label":40},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604004.html",{"kind":134,"url":135,"label":100},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AR03",{"kind":137,"url":120,"label":138},"darooyab","Emtricitabine-Tenofovir",{"pregnancy":140,"lactation":149,"pediatric":158,"geriatric":167},{"level":141,"text":142,"quote":145,"refs":146},"caution",{"fa":143,"en":144},"برچسب: داده‌های مشاهده‌ای افزایش خطر نقص مادرزادی عمده را نشان نداده‌اند.","Label: observational data have shown no increased risk of major birth defects.","Data on the use of TRUVADA during pregnancy from observational studies have shown no increased risk of major birth defects.",[147],{"source":34,"section":148},"8.1",{"level":150,"text":151,"quote":154,"refs":155},"avoid",{"fa":152,"en":153},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Women should not breastfeed if acute HIV-1 infection is suspected because of the risk of HIV-1 transmission to the infant.",[156],{"source":34,"section":157},"8.2",{"level":159,"text":160,"quote":163,"refs":164},"not-established",{"fa":161,"en":162},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of Truvada for HIV-1 PrEP in pediatric patients weighing less than 35 kg have not been established.",[165],{"source":34,"section":166},"8.4",{"level":141,"text":168,"quote":171,"refs":172},{"fa":169,"en":170},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical trials of FTC, TDF, or TRUVADA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.",[173],{"source":34,"section":174},"8.5",{"kind":176,"refs":177,"id":125},"NDA",[178],{"source":34,"section":179},"SPL approval \u002F marketing category",1792108421570]